TimothyJHobdayMD

Oncology • Rochester, MN

Assistant Professor, Oncology, Mayo Medical School

Join to view full profile

Dr. Hobday is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hobday's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1997 - 2001
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1994 - 1997
Mayo Clinic College of MedicineClass of 1994

Certifications & Licensure

AZ State Medical License 1997 - Present
MN State Medical License 1995 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Start of enrollment: 2003 Dec 01
Completed
Phase 2
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Start of enrollment: 2005 Jun 01
Completed
Phase 2
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 Mar 16
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1806 citations
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M. Wolin
The New England Journal of Medicine. 2011-02-10
1784 citations
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg, Ghassan El-Haddad, Edward M. Wolin, Andrew Eugene Hendifar, James C. Yao
The New England Journal of Medicine. 2017-01-11
11 citations
Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice.
Ariela L. Marshall, Ruchi Gupta, Diane E. Grill, Susan Mann, Kimberly Freidline
Journal of Cancer Education. 2019-12-01

Lectures

Great Debates and Updates in Gastrointestinal Malignancies
Imedex, New York, New York - 3/30/2012

Press Mentions

Living His Best Life Against the Backdrop of Incurable CancerSeptember 20th, 2019
Living in the Present, Grateful for LifeJune 6th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member